Kezar Life Sciences is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of novel small molecule therapeutics targeting protein homeostasis for autoimmune disorders. Kezar's lead drug candidate, KZR-616, leverages more than a decade of research directed by co-founder Christopher Kirk into the unique role of the immunoproteasome in immune cell biology.